UA112764C2 - Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок - Google Patents

Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок

Info

Publication number
UA112764C2
UA112764C2 UAA201308173A UAA201308173A UA112764C2 UA 112764 C2 UA112764 C2 UA 112764C2 UA A201308173 A UAA201308173 A UA A201308173A UA A201308173 A UAA201308173 A UA A201308173A UA 112764 C2 UA112764 C2 UA 112764C2
Authority
UA
Ukraine
Prior art keywords
polymorphic
pure
crystallic
particle size
bile acids
Prior art date
Application number
UAA201308173A
Other languages
English (en)
Inventor
Рудольф Вільхельм
Маркус Прьольс
Ерік Фішер
Поульсен Хейді Ванерлюнд
Original Assignee
Др. Фальк Фарма Ґмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Фальк Фарма Ґмбх filed Critical Др. Фальк Фарма Ґмбх
Publication of UA112764C2 publication Critical patent/UA112764C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується чистої поліморфної модифікації нор-УДХК або біс-нор-УДХК, або їх фармацевтично прийнятної солі. Винахід додатково пропонує фармацевтичну композицію, що містить поліморфну модифікацію винаходу й спосіб одержання поліморфної модифікації. Винахід включає фармацевтичне застосування поліморфної модифікації або фармацевтичної композиції винаходу.
UAA201308173A 2010-11-30 2011-11-30 Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок UA112764C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10193143A EP2468762A1 (en) 2010-11-30 2010-11-30 Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
PCT/EP2011/071406 WO2012072689A1 (en) 2010-11-30 2011-11-30 Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

Publications (1)

Publication Number Publication Date
UA112764C2 true UA112764C2 (uk) 2016-10-25

Family

ID=44275998

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201308173A UA112764C2 (uk) 2010-11-30 2011-11-30 Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок

Country Status (24)

Country Link
US (2) US9512167B2 (uk)
EP (2) EP2468762A1 (uk)
JP (2) JP6276592B2 (uk)
CN (1) CN103298825B (uk)
AU (1) AU2011334928B2 (uk)
BR (1) BR112013013179B1 (uk)
CA (1) CA2818984C (uk)
CY (1) CY1118036T1 (uk)
DK (1) DK2646457T3 (uk)
EA (1) EA025586B1 (uk)
ES (1) ES2597652T3 (uk)
HR (1) HRP20161187T1 (uk)
HU (1) HUE029847T2 (uk)
IL (1) IL226616A (uk)
LT (1) LT2646457T (uk)
ME (1) ME02480B (uk)
NZ (2) NZ610862A (uk)
PL (1) PL2646457T3 (uk)
PT (1) PT2646457T (uk)
RS (1) RS55211B1 (uk)
SI (1) SI2646457T1 (uk)
UA (1) UA112764C2 (uk)
WO (1) WO2012072689A1 (uk)
ZA (1) ZA201303820B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2248581T3 (es) 2001-03-12 2006-03-16 Intercept Pharmaceuticals, Inc. Esteroides como agonistas de fxr.
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
KR20190057108A (ko) * 2016-09-30 2019-05-27 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체의 결정형
EP3461485A1 (en) 2017-09-28 2019-04-03 Dr. Falk Pharma Gmbh Use of nor-ursodeoxycholic acid for reducing liver fat
WO2021130232A1 (en) 2019-12-23 2021-07-01 Medizinische Universität Wien Bile acid derivatives in the medical intervention of anxieties and/or stress symptoms
US11655240B1 (en) * 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
EP4561533A1 (en) * 2022-07-25 2025-06-04 Shilpa Medicare Limited Pharmaceutical compositions of nor-udca
EP4721745A1 (en) * 2023-05-31 2026-04-08 Shanghai Henlius Biotech, Inc. Combined product, salt and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289020B (uk) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
ITMI20012572A1 (it) 2001-12-06 2003-06-06 Istituto Biochimico Italiano Microgranuli di acido ursodesossicolico
HUE025409T2 (en) * 2005-05-12 2016-02-29 Medizinische Universität Graz Application of 24-norUDCA
CN100513415C (zh) * 2005-08-03 2009-07-15 中国人民解放军军事医学科学院毒物药物研究所 胆汁酸衍生物及其医药用途
SI2182954T1 (sl) * 2007-07-25 2019-04-30 Medizinische Universitat Graz Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

Also Published As

Publication number Publication date
RS55211B1 (sr) 2017-02-28
AU2011334928A1 (en) 2013-06-20
HK1187351A1 (zh) 2014-04-04
BR112013013179A2 (pt) 2016-09-06
CN103298825A (zh) 2013-09-11
EP2646457B1 (en) 2016-08-17
PL2646457T3 (pl) 2017-02-28
ME02480B (me) 2017-02-20
LT2646457T (lt) 2016-10-10
DK2646457T3 (en) 2016-10-10
WO2012072689A1 (en) 2012-06-07
US9512167B2 (en) 2016-12-06
BR112013013179B1 (pt) 2021-10-13
JP6276592B2 (ja) 2018-02-07
HRP20161187T1 (hr) 2016-11-04
JP2013544267A (ja) 2013-12-12
ZA201303820B (en) 2014-02-26
US20170057990A1 (en) 2017-03-02
CA2818984A1 (en) 2012-06-07
EA025586B1 (ru) 2017-01-30
CA2818984C (en) 2019-01-08
AU2011334928B2 (en) 2016-09-01
CY1118036T1 (el) 2017-05-17
NZ708988A (en) 2016-08-26
EA201300647A1 (ru) 2014-01-30
PT2646457T (pt) 2016-10-18
HUE029847T2 (en) 2017-04-28
ES2597652T3 (es) 2017-01-19
JP2017081989A (ja) 2017-05-18
EP2468762A1 (en) 2012-06-27
NZ610862A (en) 2015-07-31
JP6594917B2 (ja) 2019-10-23
CN103298825B (zh) 2016-11-23
US20140050791A1 (en) 2014-02-20
SI2646457T1 (sl) 2016-10-28
IL226616A (en) 2017-05-29
US10000526B2 (en) 2018-06-19
EP2646457A1 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
UA112764C2 (uk) Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок
IL219865A0 (en) Acid salt forms of polymer-drug conjugates, compositions comprising the same, methods of producing the same and uses thereof
IL225725A0 (en) Crystalline derivative 6,7-saturated-7-morphine carbamoyl and method for its production
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
SG10201804817TA (en) Delayed release compositions of linaclotide
PL2600865T3 (pl) Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
IN2012DN03182A (uk)
IN2015DN01119A (uk)
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2012016683A3 (en) Oral dosage form of pregabalin
MX2014004196A (es) Citramida de rasagilina.
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
UA106386C2 (uk) Спосіб синтезу івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用
PH12013501055A1 (en) Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
WO2011023954A3 (en) Polymorphic forms of manidipine
ZA201303692B (en) Diphenyl-amine derivatives:uses,process of synthesis and pharmaceutical compositions
IN2014DN03010A (uk)
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
PH12013501054A1 (en) Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
PH12013500210A1 (en) Highly crystalline valsartan
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
MY153904A (en) Method of producing pharmacologically pure crystals